Cardiac Resynchronization Therapy Market Size, Share & Trends Analysis Report By Product (CRT-Defibrillator, CRT-Pacemaker), By End-use (Hospitals, Cardiac Centers, Others), By Region,- Industry Analysis, Share, Growth, Regional Outlook and Forecasts, 2025-2034

Cardiac Resynchronization Therapy Market Size and Trends

The global cardiac resynchronization therapy market was valued at USD 4.88 billion in 2024 and is projected to reach USD 7.87 billion by 2034, registering a CAGR of 4.9% from 2025 to 2034. The global cardiac resynchronization therapy market growth is attributed to the growing product developments.

Cardiac Resynchronization Therapy Market Key Takeaways

• By region, North America dominated the cardiac resynchronization therapy market in 2024.  
• By region, Asia Pacific is expected to grow fastest during the forecast period. 
• By product insights, the CRT-Defibrillators segment dominated the market share in 2024. 
• By product insights, the CRT-Pacemaker segment is expected to grow fastest during the forecast period. 
• By end-use insights, the hospitals segment dominated the market share in 2024. 
• By end-use insights, the Cardiac Center segment is expected to grow fastest during the forecast period

Cardiac Resynchronization Therapy Market By Overview

The cardiac resynchronization therapy market deals with medical treatment designed to improve the heart's function in patients with heart failure, especially with regular heart rhythms. It involves the use of a specialized defibrillator or pacemaker that sends electrical impulses to the heart to help coordinate the timing of the heart's contractions. Leading to reduced efficiency in pumping blood, the heart's chambers may beat out of sync, in patients with heart failure. This therapy improves the coordination between the heart's left and right ventricles, by resynchronizing the heart's electrical impulses. This treatment significantly reduces symptoms such as fatigue and shortness of breath and improves quality of life.

The cardiac resynchronization therapy market is witnessing significant growth due to factors such as growth in emerging markets, increasing demand for therapies such as cardiac resynchronization therapy, rising technological advancements in devices, and increasing treatment options for the growing prevalence of cardiovascular diseases. In addition, the growing geriatric population, the increasing availability of cardiac resynchronization therapy devices, increasing awareness about heart health, and rising sedentary lifestyles are further expected to enhance the growth of the cardiac resynchronization therapy market.

Key Trends Contributing Market Trends

• Introduction of newer models: The introduction of newer models that integrate additional functionalities such as technological improvements is expected to drive market growth.
• Rising constant innovation: The increase in research and constant innovations in intensive care solutions is driving the growth of the cardiac resynchronization therapy market during the forecast period.
• Advancements in intensive care: Rising innovations in intensive care research commonly focus on refining treatment therapeutic and modalities devices and improving diagnostic tools are further expected to drive the market growth during the forecast period.

Report Scope of Cardiac Resynchronization Therapy Market

Integration with Machine Learning and AI Creates Growth Opportunities

The integration of machine learning and artificial intelligence in cardiac resynchronization therapy presents significant growth opportunities in the market. AI-generated predictive algorithms and diagnostic tools can help doctors make more accurate decisions for cardiac resynchronization therapy patients. Furthermore, AI can ensure the most effective treatment for patients and optimize the programming of the devices. Leading to better outcomes and broader market adoption, the treatment process can become more effective and personalized by combining these advanced technologies with existing cardiac resynchronization therapies, which further enhances the growth of the cardiac resynchronization therapy market in the coming years.

High Cost of Treatment May Hamper Market Growth

The high cost of procedures and devices is one of the major restraints hindering market growth. The expenses associated with device maintenance and implantation can be prohibitive for some patients particularly in low-income class, while the therapy is highly effective. The high out-of-pocket costs and insurance coverage varies by region can create challenges in this treatment for a significant portion of the population. These factors are expected to restrain the growth of the cardiac resynchronization therapy market.

Segment Insights

Cardiac Resynchronization Therapy Market By Product Insights

The CRT-Defibrillators segment dominated the cardiac resynchronization therapy market in 2024. The segment growth in the market is attributed to the rising product advancements by major market players, the increasing prevalence of cardiac diseases, and the increasing geriatric population across the globe. Whereas the CRT-Pacemaker segment is expected to grow fastest during the forecast period. CRT-Pacemaker enables CRT to coordinate the timing between the left and right sides of the heart. CRT-Pacemaker also improves the heart, survival function, and quality of life, which further drives the segment growth.

For instance, in February 2024, Coimbatore Medical College Hospital (CMCH) authorities successfully implanted a Cardiac Resynchronization Therapy-Defibrillator (CRT-D) device in a patient with heart failure.

Cardiac Resynchronization Therapy Market By End-use Insights

The hospitals segment dominated the cardiac resynchronization therapy market in 2024. The segment growth in the market is driven by the increasing prevalence of cardiac failure and high consumption of CRT devices in hospitals. In addition, the Cardiac Center segment is expected to grow fastest during the forecast period. The segment growth in the market is driven by the prevalence of cardiovascular diseases and the increasing number of cardiac specialty centers.

Cardiac Resynchronization Therapy Market By Regional Insights

North America dominated the cardiac resynchronization therapy market in 2024. The market growth in the region is attributed to the increasing healthcare awareness among the population, insurance coverage, and the increasing presence of well-developed healthcare providers. In addition, increasing demand for cardiac treatment solutions and advanced medical infrastructure are further expected to drive the growth of the cardiac resynchronization therapy market in the region. The U.S. and Canada are dominating countries driving the market growth. The increasing risk of developing chronic cardiac conditions, sedentary lifestyle and growing regulatory approvals are contributed to propel the market growth in the U.S.

Asia Pacific Market Trends

Asia Pacific is expected to grow fastest during the forecast period. The market growth in the region is attributed to the increasing the growing prevalence of cardiac diseases, strategic initiatives by key companies, improvement in economic conditions, growing geriatric population, and developing healthcare infrastructure. China, India, Japan, and South Korea are the fastest growing countries in the market. China is the fastest growing country in the healthcare industry leading to brand recognition and cost-effectiveness, a robust product pipeline, and a wide portfolio.

Some of The Prominent Players in The Cardiac Resynchronization Therapy Market Include:

• Jude Medical 
• Japan Lifeline Co., Ltd. 
• Koninklijke Philips N.V. 
• Medico S.p.A 
• BIOTRONIK SE & Co. KG 
• Osypka Medical GmbH 
• Boston Scientific Corporation

Cardiac Resynchronization Therapy Market Recent Developments

• In December 2024, DPU Super Specialty Hospital launched the Pediatric Cardiac Intensive Care Unit (ICU). This ICU offers specialized care for children with cardiac diseases.
  
  
• In February 2024, a pioneering company in the field of Cardiac Rhythm Management, MicroPort® CRM launched the GALI™ SonR® Cardiac Resynchronization Therapy and Defibrillation device (CRT-D) and NAVIGO™ 4LV left ventricular pacing leads in Japan.

Segments Covered in the Report

This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2034. For this study, Nova one advisor, Inc. has segmented the Cardiac Resynchronization Therapy Market

By Product

• CRT-Defibrillator
• CRT-Pacemaker

By End-use

• Hospital
• Cardiac Center
• Others

By Regional

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)